TransMedics

TransMedics generates revenue through the sale and placement of Organ Care System (OCS) consoles and single-use perfusion sets for lung, heart, and liver transplants, and through its National OCS Program (NOP), which charges transplant centers a service fee for organ retrieval and management. As of its most recent public disclosures, these two lines constitute the entirety of reported operations.

The OCS holds FDA premarket approval for lung, heart, and liver indications. The heart indication includes both donation after brain death (DBD) and donation after circulatory death (DCD) donors, the latter approved following a supplemental PMA. No other warm-perfusion platform holds an equivalent breadth of US transplant approvals.

The NOP is TransMedics’ clinical service arm that deploys company-employed transplant surgeons and perfusionists to donor hospitals. They recover organs, place them on the OCS, and transport them to the recipient center, allowing hospitals to accept more organs without expanding their own retrieval staffing or logistics capacity.

There is no publicly available evidence that TransMedics operates an investment fund, manages outside capital, or functions as a family office. All primary-source materials from the firm describe a commercial medical-device and clinical-services business.

Standard cold storage stops metabolism to buy time, but the clock begins degrading tissue immediately. The OCS keeps the organ warm, perfused with oxygenated blood, and metabolically active, which extends the viable out-of-body window and lets surgeons assess organ function before transplant — a shift from a static preservation model to an active organ-management one.